Search for "influenza"
Answer created by AI
- Like
- Disike
AI result is experimental
Generating Answer...
-
Clinical Trials (185)
-
Infectious Disease (119)
-
Therapy Area (83)
-
Covid-19 (80)
-
Technology (52)
-
Approvals (45)
-
The next chapter of clinical trial services (43)
-
COVID Cross-sector Impact Brief (41)
-
Suvoda WP (41)
-
Country Risk Report Q4 2021 - Professional Services (38)
-
Genomics (37)
-
API Manufacturers (36)
-
Drug Development (32)
-
Oracle NAS WP (14)
-
Respiratory (11)
-
Immunology (10)
-
Clinical Trials Arena (7)
-
Global Healthcare and Pharma Market Outlook (7)
-
Agilent WP (5)
-
Cytiva-Cell & Gene Therapy WP 2 (5)
No Filter Selected
-
News Analysis and Comments (272)
-
Projects (26)
-
Press Releases (2)
-
Suppliers (2)
-
White Papers (1)
No Filter Selected
-
Clinical Trials (2)
-
Clinical Trial Monitoring (1)
-
Contract Research Organization (1)
-
Events and Publications (1)
-
Water Purification (1)
No Filter Selected
-
United States (95)
-
North America (30)
-
United Kingdom (22)
-
Global (20)
-
Europe (19)
-
China (12)
-
Australia (10)
-
Asia-Pacific (9)
-
Japan (8)
-
India (6)
-
Germany (4)
-
Belgium (3)
-
Canada (3)
-
Taiwan (Province of China) (3)
-
Brazil (2)
-
Middle East & Africa (2)
-
South Korea (2)
-
Switzerland (2)
-
Argentina (1)
-
France (1)
No Filter Selected
-
Other Innovation Areas (6)
No Filter Selected
Development of universal vaccines represents an emerging trend in influenza
Universal influenza vaccines are created to provide protection against more strains of the virus than the quadrivalent influenza vaccines.
WHO trivalent recommendations expected to reshape global influenza vaccine market
The World Health Organization (WHO) has recently advised a reversion to trivalent (three-strain) influenza vaccines for the 2024 southern hemisphere influenza season, which will begin around April and last until September.
Novavax enrols first patient in Phase II trial of quadrivalent seasonal influenza VLP
US-based biopharmaceutical firm Novavax has started patient enrolment in a Phase II clinical trial of its recombinant quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate (Seasonal Influenza VLP).
Doherty and Kirby Institute study antibody-based therapy for influenza B
The researchers revealed insights on the complex mechanisms underlying antibody-based therapies for the patients.
IDWeek 2019: Seasonal influenza vaccines prove their worth, but better vaccines are still needed
Annual vaccinations reduced the number of hospitalisations in children by 50%, not only in patients with pre-existing conditions but also in healthy children (40% of the cases).
Public-private partnerships continue to play a critical role in influenza vaccine R&D
On March 9, the FDA Commissioner, Scott Gottlieb, testified before a Congressional committee regarding the 2017–2018 influenza season. Gottlieb’s testimony highlighted ongoing collaboration between the US government and biopharmaceutical industry for the development of more efficacious influenza vaccines.
2023-24 seasonal flu activity remains elevated
GlobalData epidemiologists forecast more than 470,000 cases of lab-confirmed influenza in the US in 2024.
FluGen doses first subject in new study of M2SR for influenza
FluGen has dosed the first subject in a new clinical trial evaluating the M2SR vaccine to treat subjects with an influenza virus genetically mismatched by six years from the influenza strain utilised in the vaccine.
Seasonal influenza extends later than previous seasons
The 2021–22 influenza season has had an unusually high amount of activity late in the season, with two peaks in positive tests.
T-705 - Antiviral Drug for Influenza by Toyama Chemical of Japan
T-705 is a novel oral agent indicated for the treatment of influenza that is under development by Toyama Chemical of…
Snapshot H1N1 (swine influenza) – the post-pandemic pipeline
Few modern pandemics created as much global furore as the H1N1 swine flu outbreak which struck in 2008. The scale and spread of the outbreak created a very real sense of fear about mutating virus strains and created a boom for a new pipeline of vaccines and antivirals. Using detailed market data, we find out what the future holds for the industry in this post-pandemic period.
Vaxart begins patient enrollment in influenza B Phase I trial
US-based biotechnology firm Vaxart has started enroling patients in a Phase I trial to evaluate its influenza B tablet vaccine.
Fludase - Experimental Antiviral Drug for Influenza
NexBio, a US start-up biopharmaceutical company that specialises in developing antiviral agents, has pioneered the development of Fludase (DAS181), an…
CureVac highlights shift in seasonal influenza vaccines development pipeline
During the past ten reported US influenza seasons, vaccine effectiveness was approximately 40%, but reached as low as 19% in 2014-2015.
NIH initiates Phase I trial of universal flu vaccine
The US National Institutes of Health (NIH) has announced the launch of a Phase I clinical trial to evaluate a universal influenza vaccine candidate, called H1ssF_3928, in healthy volunteers.
National Immunization Awareness Month a reminder for seasonal influenza vaccinations
NIAM comes at an opportune time, as annual influenza vaccinations will begin to be available in the coming weeks.
Visterra begins Phase IIa trial of VIS410 to treat hospitalised patients with influenza A
US-based clinical-stage biopharmaceutical company Visterra has commenced its Phase IIa clinical trial of VIS410 to treat hospitalised patients with influenza A.
Novavax begins Phase II study for Covid-19-Influenza vaccines
The trial will assess the safety and effectiveness of various formulations of CIC and flu vaccine candidates.
CDC Findings: 2021-22 US flu vaccine efficacy is concerningly low
The currently available flu vaccines protect the population against the four most common influenza viruses in circulation: A(H1N1)pdm09, A(H3N2), B/Victoria…
From pandemic to twindemic: What will the 2021–2022 flu season bring?
Measures imposed by governments across the world have helped to curb the spread of influenza and other infectious diseases.